Core Points - Corbion has initiated a €10 million share buyback program announced on 1 September 2025 [1] - As of 5 September 2025, a total of 83,962 shares have been repurchased at an average price of €17.3463, totaling €1,456,431.48 [1] - The total amount spent on repurchased shares represents 14.56% of the overall share buyback program [1] Weekly Update - Corbion publishes a weekly overview every Monday detailing the progress of the share buyback program on its website [2] - This overview includes information on the daily amount of repurchased shares and individual share purchase transactions [2]

Core Insights - Faraday Future is preparing for the 919 Futurist Day & Stockholders' Community Day on September 19, 2025, to celebrate the one-year anniversary of the FX Strategy and engage with stockholders [2][8] - The event will showcase the FX Super One's interior and product highlights, along with updates on its homologation in the U.S. and launch plans for the Middle East [3][4] - The company is focusing on its Crypto Flywheel strategy, which includes the C10 Treasury and aims to maximize value creation for stockholders through a dual-engine growth system [4][9] Company Updates - The FX Super One has been actively showcased in key states, including participation in the Luxury Transportation Exchange event in Las Vegas, generating strong interest from industry partners [5][6] - Under the 10b5-1 share purchase plan, the Co-CEO has invested approximately $180,000 in FFAI common stock, demonstrating confidence in the company's long-term strategy [7] - A Special Meeting of Stockholders will be held on September 19 to seek approval for key proposals, including increasing shares for the equity incentive plan to attract and retain talent [8] Crypto Strategy - The C10 Treasury has expanded with a new allocation of $2 million in crypto coins, maintaining an investment strategy of 80% passive index and 20% active management [9] - Staking of C10 crypto coins has begun, expected to enhance yield, mitigate risk, and support ecosystem participation [10] - The company is committed to its strategic investments in cryptocurrencies, focusing on LINK and BNB as core assets [9][10]

Company Overview - InnoCare Pharma is a leading biopharmaceutical company focused on developing treatments for cancer and autoimmune diseases, with a commitment to addressing unmet medical needs globally [5] Product Approval - HIBRUKA (orelabrutinib) has received approval from the Health Sciences Authority (HSA) of Singapore for treating adult patients with relapsed or refractory marginal zone lymphoma (R/R MZL) [1][2] - This marks the second indication approval for orelabrutinib in Singapore, following its previous approval for other indications [2] Product Efficacy and Safety - Orelabrutinib is a highly selective BTK inhibitor that has shown good efficacy and safety in treating R/R MZL, providing a new treatment option for local lymphoma patients [2] - The drug's high target selectivity minimizes off-target effects, enhancing both safety and efficacy [2] Market Context - Marginal zone lymphoma (MZL) is an indolent B-cell non-Hodgkin's lymphoma primarily affecting middle-aged and elderly patients, with an increasing annual incidence globally [3] - Patients with R/R MZL often lack effective treatment options after first-line therapy [3] Previous Approvals - In April 2025, orelabrutinib was approved in China for the first-line treatment of chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) and has received approvals for three other indications, including R/R CLL/SLL, R/R mantle cell lymphoma (MCL), and R/R MZL, all included in China's National Reimbursement Drug List [4]

Core Viewpoint - ACM Research, Inc. has launched its first Ultra Lith KrF track system aimed at enhancing front-end semiconductor manufacturing, which signifies the company's commitment to addressing lithography challenges in mature-node devices [1][3]. Group 1: Product Launch and Features - The Ultra Lith KrF track system expands ACM's lithography product line, offering high-throughput performance, advanced thermal control, and real-time process monitoring [1][3]. - The system features a flexible process module configuration with 12 spin coaters and 12 developers, supported by 54 hot plates for various temperature processing, achieving a throughput greater than 300 wafers per hour [3][2]. - The system incorporates proprietary backside particle removal unit (BPRV) technology to minimize cross-contamination risk and includes an integrated wafer-scale outlier inspection (WSOI) unit for real-time process variation detection [3][2]. Group 2: Market Position and Strategy - The launch reflects ACM's strategy to enhance its presence in front-end process equipment and to cater to the growing demand for mature-node devices, which are believed to represent a significant portion of global semiconductor output [3][2]. - By offering both ArF and KrF track systems, ACM aims to provide seamless fab integration and greater manufacturing flexibility across diverse applications [3][2]. Group 3: Company Overview - ACM Research, Inc. develops, manufactures, and sells semiconductor process equipment, including cleaning, electroplating, and packaging tools, aimed at improving productivity and product yield for semiconductor manufacturers [5].

Core Viewpoint - Abaxx Technologies Inc. is collaborating with Qingdao International Energy Exchange to enhance the physical liquefied natural gas (LNG) market in Asia, aiming to connect international suppliers with China's demand centers and improve the overall LNG trading ecosystem [1][2][4]. Group 1: Collaboration Details - The collaboration will combine Abaxx's LNG futures and clearing infrastructure with Qingdao's established position in China's energy markets [2]. - Key focus areas include developing mechanisms for cross-border LNG trade, creating transparent pricing benchmarks for the Asia-Pacific region, and offering innovative risk management solutions [9]. Group 2: Strategic Importance - This partnership is expected to strengthen Asia's LNG marketplace by enhancing liquidity, transparency, and risk management tools, thereby supporting efficient cross-border trade and the transition to cleaner energy sources [2][4]. - The collaboration reflects a shared commitment to advancing sustainable energy solutions between Singapore and China [4]. Group 3: Company Overview - Abaxx Technologies is focused on building smarter markets through better tools, benchmarks, and technology to address societal challenges, including the energy transition [5]. - The company operates Abaxx Exchange and Abaxx Clearing, providing market infrastructure for various commodities, including LNG, carbon, and precious metals [7].

Core Insights - Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases [1][3] - The company will hold a conference call and webcast to discuss the results of the Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) on September 8, 2025 [1] Company Overview - Dianthus Therapeutics is based in New York City and Waltham, Massachusetts, and is led by an experienced team of biotech and pharma executives [3] - The company aims to design and deliver novel, best-in-class monoclonal antibodies with improved selectivity and potency for treating severe autoimmune and inflammatory diseases [3]

SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that company’s product, recombinant humanized anti-IL-17A monoclonal antibody (code: JS005) has achieved positive results in a multi-center, randomized, double-blind, parallel, placebo-controlled pivotal registrational Phase 3 clinical ...

维多利亚，塞舌尔, Sept. 07, 2025 (GLOBE NEWSWIRE) -- 领先的加密货币交易所和 Web3 公司 Bitget 将与 Saturnia Design 合作举办独家活动 Bitget Elite Day London。 该活动将于 9 月 10 日在 The Royal Society（英国皇家学会）举行，旨在通过关注区块链的发展如何超越投机属性，对现实世界产生可持续的影响，为欧洲数字金融建立切合实际的长远愿景。 去年 6 月，Bitget Elite Day 在布达佩斯大获成功，众多不同领域的业内人士齐聚一堂。伦敦精英日也将以此为基础，进一步加强对话。 这次活动将汇集全球领导者和创新者，旨在直面一个迫在眉睫的关键问题：区块链可以在脱离加密货币的情况下蓬勃发展吗？加密货币在未来十年是否仍保持相关性？ 讨论将由思想领袖小组主导，其中包括 GVG Group 首席执行官兼创始人 Shamit Ghosh 和 Saturnia Design 联合创始人 Mike Vitez。 他们将拨开市场迷雾，探讨一些重要话题，例如去中心化金融 (DeFi) 在传统银行业务中的角色、代币化带来的新 ...

Core Insights - HKC Group makes its European debut at IFA 2025, showcasing innovation across its three brands: HKC, KOORUI, and ANTGAMER [1] - Each brand unveils breakthrough products, emphasizing HKC's commitment to the European market [1] HKC Brand Highlights - HKC introduces the G32M12Max, a 32-inch UHD Mini LED display with over 10,000 local dimming zones, 2100 nits peak brightness, and HDR1400 certification, surpassing mainstream competitors [2] - The G32M12Max features a 240Hz refresh rate, 99% DCI-P3 color coverage, HDMI 2.1, DP 1.4, and 90W USB-C, catering to gamers and creators [2] KOORUI Brand Highlights - KOORUI presents the S4941XO, a 49-inch QD-OLED curved ultra-wide monitor with a 32:9 aspect ratio, 5120×1440 resolution, and 240Hz refresh rate [3] - The S4941XO offers 0.03ms response time, HDR visuals, 98% DCI-P3 coverage, and 10-bit depth, ideal for immersive play and multitasking [3] ANTGAMER Brand Highlights - ANTGAMER unveils the ANT257PF, the world's first mass-produced 750Hz esports monitor, designed for professional tournaments [4] - ANTGAMER also introduces the ANT275ZQE, a 27-inch OLED gaming monitor with dual-mode performance—QHD at 540Hz or HD at 720Hz, featuring DisplayHDR True Black 500 certification [5] Strategic Positioning - By showcasing its three brands together, HKC signals readiness to collaborate with European distributors, retailers, and users [6] - Live demos and hands-on sessions are available at Booth H23-109, with press resources and giveaways for accredited media [6] Company Overview - HKC Group is a global leader in display technology, focusing on advanced R&D, large-scale production, and multi-brand operations [7] - The group aims to deliver innovative monitors for diverse users worldwide, making high-performance displays more accessible [7]

Core Insights - Encaleret demonstrated significant efficacy in normalizing blood and urine calcium levels in post-surgical hypoparathyroidism patients, with 80% achieving normal levels within 5 days of treatment initiation compared to 0% on conventional therapy at baseline [1][6] - The treatment was well-tolerated, with no serious adverse events reported during the study [1] - BridgeBio plans to initiate a registrational clinical study for encaleret in chronic hypoparathyroidism in 2026 based on the promising Phase 2 results [1][3] Company Overview - BridgeBio Pharma, Inc. is focused on developing transformative medicines for genetic diseases, with a pipeline that includes early science to advanced clinical trials [5] - The company was founded in 2015 and aims to leverage advances in genetic medicine to expedite patient care [5] Study Details - The Phase 2 proof-of-concept study evaluated the PTH-independent effects of encaleret on renal calcium handling in ten participants with post-surgical hypoparathyroidism, administered at 162 mg twice daily for up to 5 days [2] - Calcitriol was stopped one day prior to the first dose, and calcium levels were titrated based on blood calcium after starting encaleret [2] Additional Findings - Encaleret treatment resulted in a rapid and sustained reduction in fractional excretion of calcium in nine participants, supporting its potential as an orally-administered treatment option for chronic hypoparathyroidism [6] - Data from preclinical studies of infigratinib were also presented, showing significant improvements in bone growth and skull development in relevant mouse models, indicating broad potential for treating skeletal conditions [4]